Clinical Trial Update: NNRTI/PI Toxicity Switch to Darunavir Study [Phase 4]

View source ↗

Summary

A Phase 4 HIV trial evaluating switching from an NNRTI/PI regimen to darunavir due to toxicity was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PREZISTA (darunavir)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 4 | Status: TERMINATED